Correlates of Hepatitis C Serostatus Disclosure in Rural Appalachian Kentucky by Hofmeister, Megan G.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Public Health (M.P.H. 
& Dr.P.H.) College of Public Health 
2016 
Correlates of Hepatitis C Serostatus Disclosure in Rural 
Appalachian Kentucky 
Megan G. Hofmeister 
University of Kentucky 
Follow this and additional works at: https://uknowledge.uky.edu/cph_etds 
 Part of the Public Health Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Hofmeister, Megan G., "Correlates of Hepatitis C Serostatus Disclosure in Rural Appalachian Kentucky" 
(2016). Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.). 76. 
https://uknowledge.uky.edu/cph_etds/76 
This Graduate Capstone Project is brought to you for free and open access by the College of Public Health at 
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my capstone and abstract are my original work. Proper attribution has been 
given to all outside sources. I understand that I am solely responsible for obtaining any needed 
copyright permissions. I have obtained needed written permission statement(s) from the 
owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic 
distribution (if such use is not permitted by the fair use doctrine) which will be submitted to 
UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s capstone including 
all changes required by the advisory committee. The undersigned agree to abide by the 
statements above. 
Megan G. Hofmeister, Student 
April Young, PhD, MPH, Committee Chair 
Dr. Linda Alexander, Director of Graduate Studies 

 1 
Abstract 
 
Aim: To identify demographic, behavioral, and interpersonal characteristics associated with 
hepatitis C (HCV) serostatus disclosure among adult, rural, high-risk people who use drugs 
(PWUD) in Appalachian Kentucky. 
Methods: HCV antibody-positive participants (n=243), drawn from the fifth follow-up 
assessment of a longitudinal study of rural PWUD, completed interviewer-administered 
questionnaires eliciting demographic and interpersonal characteristics, risk behaviors, and 
information on HCV disclosure. Correlates of HCV disclosure were assessed using multivariate 
logistic regression. 
Results: Most (69.1%) reported disclosing their HCV-positive status to at least one of their 
social referents (current or past sex partners, current or past injection drug use (IDU) partners, 
family, friends, or spouse), but few told the people with whom they inject drugs (3.8% disclosed 
to current, and 1.4% disclosed to past IDU partners). In multivariate analysis, adjusting for 
confounders and time since HCV diagnosis, older age (AOR=0.96, 95% CI [0.93, 1.00]) and 
lifetime history of drug treatment (AOR=0.39, 95% CI [0.22, 0.69]) were associated with 
decreased odds of HCV disclosure.  
Conclusions: While most participants reported HCV disclosure, the almost complete absence of 
disclosure to current or former injection drug use partners was concerning. Although further 
research is warranted, it is clear that interventions are needed to encourage HCV disclosure 
among those most at risk of transmitting, or becoming infected with, HCV.  
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Introduction 
 
Current estimates suggest that at least 3.5 million individuals (range 2.5 million – 4.7 million)1 
are infected with hepatitis C virus (HCV) in the United States, making HCV the most common 
blood-borne infection in the United States. The Centers for Disease Control and Prevention 
(CDC) estimates that nearly 30,000 incident cases of acute HCV occurred in 2013 in the United 
States.2 Between 2006-2012, state surveillance data from Central Appalachia (Kentucky, 
Tennessee, Virginia, and West Virginia) demonstrated a 364% increase in the number of acute 
HCV infections among persons ≤30 years old.3 Among those cases of acute HCV in Central 
Appalachia with identified risk information, injection drug use (IDU) was reported in almost 
three-fourths of cases (73%).3 HCV is primarily transmitted through percutaneous exposure to 
contaminated blood. As a consequence, IDU is the leading means of HCV transmission in the 
United States.4,5 Despite the existence of national screening recommendations based on risk 
factors and birth cohort, many individuals are unaware that they are infected with HCV. Several 
recent studies suggest that a substantial proportion (40-85%) of HCV-positive individuals are 
unaware of their infection status.4 One study found that among persons who inject drugs 
(PWID), 72% of those who were HCV-positive were unaware of their status.6 
 
Individuals with both acute and chronic HCV infections are often asymptomatic.7,8 
Consequently, many HCV-infected individuals never seek testing. These factors contribute to the 
substantial lack of awareness of serostatus among HCV-positive individuals, which places risk 
partners (particularly people with whom they inject or share injection equipment) of infected 
individuals at risk of unwittingly acquiring HCV. Although highly successful curative treatments 
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have been developed in recent years, these medications are prohibitively expensive.9 Among 
high-risk populations (such as PWID) that frequently lack access to health insurance or 
healthcare, reliance on curative medical treatment to stop the spread of HCV is not yet a viable 
and scalable prevention strategy. Primary prevention of HCV infection is the most desirable 
public health approach to reducing morbidity, mortality, and the economic burden associated 
with HCV infection.  
 
Serostatus disclosure has been described as a cornerstone of primary prevention strategies related 
to human immunodeficiency virus (HIV) transmission between sexual partners.10,11 HCV 
disclosure can similarly serve as an important preventive public health measure for HCV 
infection. Disclosure of HCV allows the social contacts of an infected individual the opportunity 
to make informed decisions regarding engaging in risk behaviors, thus potentially reducing HCV 
transmission risks. Research indicates that individuals who believe their injecting partner is 
HCV-positive are more likely to practice safer injecting habits (i.e., not inject with someone 
else’s used needle/syringe).12   
 
While there have been numerous efforts to determine correlates of HIV disclosure,10,11,13-15 
comparatively less research has been published investigating the factors associated with 
disclosure of HCV. Additionally, studies examining disclosure of HIV more frequently focus on 
serostatus disclosure among sexual partners; findings from this research may not be applicable to 
understanding disclosure of HCV status given that sexual transmission of HCV is rare16 and 
percutaneous transmission through shared needles or injection equipment among PWID is most 
common.4,5,8 Similarly, the fact that HIV disclosure is mandatory in many settings17 while HCV 
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disclosure is not suggests that the factors impacting HIV disclosure may differ from those 
impacting HCV disclosure.  
 
Social stigma surrounding disease status disclosure, particularly of infectious diseases perceived 
as being acquired through stigmatized risk behaviors (e.g., illegal drug use), can negatively 
impact access to health care, employment, and social support.18 HCV disclosure has been 
described in the literature as a complex and emotionally difficult endeavor, with fear of a 
negative reaction, rejection, or stigmatization commonly cited as barriers to HCV-positive status 
disclosure.18,19 Studies among current PWID also found that PWID perceive HCV infection as 
inevitable and ubiquitous,20 and suggested that this fatalistic attitude could result in ambivalence 
about the need for HCV disclosure.21 Results from a cross-sectional survey in Australia revealed 
that individuals who reported being advised by someone at the time of diagnosis to tell no one or 
only close family members disclosed their HCV-positive status less widely than those who did 
not receive the same advice,22 suggesting that social influences may have a profound impact on 
an individual’s disclosure practice. 
 
Much of the published literature related to HCV disclosure has been conducted internationally, 
primarily among PWID in urban settings,18-20,22-26 and most of the studies anecdotally report 
correlates of HCV disclosure rather than focusing on disclosure as the primary research outcome. 
Relatively little is known about factors that influence HCV-positive disclosure among high-risk 
populations in rural settings. Appalachian Kentucky is an economically disadvantaged region 
that suffers from worse mortality rates among young and middle-aged adults than many less 
developed countries.27 A recent study demonstrated that annual increases in acute HCV 
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incidence among young (30 years) PWID in the United States were at least twice as high in 
rural jurisdictions as urban jurisdictions.28 The largest increases noted in the study were in rural 
jurisdictions in or nearby Appalachian counties.28 When considered in combination with the 
recent significant increase in acute HCV infections among persons 30 years in Kentucky, 
Tennessee, Virginia, and West Virginia,3 the data suggest that Central Appalachia is a current 
epicenter of HCV incidence in the United States. The purpose of this analysis is to identify 
demographic, behavioral, and interpersonal characteristics associated with HCV serostatus 
disclosure among rural, high-risk drug users in Appalachian Kentucky.  
 
Methods 
 
Study Design 
Data were collected from drug users (n=415) completing their fifth follow-up assessment in the 
ongoing, longitudinal Social Networks among Appalachian People (SNAP) study. The overall 
goal of the SNAP study is to analyze risk factors for HIV, HCV, and HSV-2 in the context of 
drug users’ social networks. Participants (n=503) were recruited through respondent-driven 
sampling29,30 between November 2008 and September 2010 from an Appalachian county in 
eastern Kentucky (explained in detail elsewhere31). Respondent-driven sampling has previously 
been shown to be an effective technique for the recruitment of rural drug users.32 The original 
participants, or seeds, were recruited through outreach workers, community informants, and 
flyers posted at the study site, and had a lifetime history of IDU. Once the seeds completed their 
baseline interviewer-administered questionnaire, they were given three coupons and asked to 
recruit drug-using peers (irrespective of injection status).  
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Individuals eligible for study participation were at least 18 years old, resided in Appalachian 
Kentucky, and had used prescription opioids, cocaine, heroin, or methamphetamine to get high in 
the prior 30 days. All participants received copies of the consent form and provided signed 
documentation of informed consent. Participants were compensated for their time ($50), and 
those seeds whose coupons were redeemed (i.e., by a peer who was eligible for, and completed 
the baseline interviewer-administered questionnaire) received an additional $10 per redeemed 
coupon. Participants completed interviewer-administered surveys and HCV testing 
approximately every six months. For the baseline assessment and the first three follow-up visits, 
trained study staff tested participants for antibodies to HCV using the Home Access test (Home 
Access Health Corporation, Hoffman Estates, IL), explained in detail elsewhere.33 For all 
subsequent visits participants were tested using the OraQuick HCV rapid antibody test.34 All 
participants were provided with their test results, either in person or by telephone, and pre- and 
posttest counseling was provided according to CDC guidelines. Participants who tested positive 
for HCV were provided with information about local healthcare resources for additional testing 
and treatment. The Institutional Review Board at the University of Kentucky approved the study 
protocol. 
 
A total of 415 participants (82.5% of the original sample) completed the fifth follow-up 
assessment. Participants lost to follow-up were less likely to be unemployed (2=9.70, p=0.002) 
than those retained in the study, but were otherwise not significantly different from those 
remaining in the analysis in terms of demographic characteristics or HCV serostatus. For the 
fifth follow-up assessment (3.8–5.3 years since participant enrollment), questions were added to 
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examine whether participants who had tested HCV antibody-positive at baseline or at any point 
during the study (n=243) had disclosed their HCV-positive status to others. Specifically, 
participants were asked, “After testing positive (here–at this location) for hepatitis C did you tell 
(please check all that apply): [your current sex partner, past sex partners, current injection drug 
use partners (people you inject with), past injection drug use partners (people you inject with), 
family member(s), close friend(s), spouse (if married)].”  
 
To assess correlates of HCV disclosure, a dichotomous variable was created to indicate whether 
or not participants disclosed their HCV-positive status to anyone. Dichotomization was 
necessary because the limited number of participants disclosing to most of the identified person-
type categories did not provide sufficient power to identify statistically significant differences in 
demographic, behavioral, or interpersonal characteristics between those HCV-positive 
individuals who had disclosed or had never disclosed their HCV-positive status by person-type.           
 
Demographic, behavioral, and interpersonal data were also obtained through the interviewer-
administered questionnaire. Demographic characteristics included gender, age (years), race, 
education, marital status, and unemployment. Additional characteristics, including lifetime 
history of IDU, lifetime history of drug treatment, and time since HCV diagnosis (years), were 
also assessed. Finally, interpersonal characteristics included whether the participant: was 
dependent on someone else for the majority of their support, self-reported spending most free 
time alone (rather than with family or friends), and had significant periods experiencing serious 
problems getting along with others during his/her lifetime. The latter interpersonal characteristic 
was assessed with the question, “Have you had significant periods in which you have 
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experienced serious problems getting along with your [mother, father, brothers/sisters, sexual 
partner/spouse, children, close friends, neighbors, co-workers] in your life?” Data were 
dichotomized to a negative response if participants denied serious problems with all possibly 
identified social referents, and to an affirmative response if participants acknowledged serious 
problems with any of the possibly identified social referents. The resultant covariate is hereafter 
referred to as ‘social conflict.’ 
 
Analysis 
Logistic regression was used to explore associations between HCV disclosure and demographic, 
behavioral, and interpersonal characteristics. All analyses were conducted using SAS software, 
version 9.4 (SAS Institute; Cary, NC, USA).35 
 
A confounding analysis was completed to aid in covariate selection for the final model. Changes 
in the estimated, unadjusted odds ratio between independent variables identified as being 
associated with disclosure in the literature (e.g., gender and education)22,26 and through 
univariate logistic regression analysis (e.g., lifetime history of drug treatment) and HCV 
disclosure were examined in the presence and absence of other covariates that could act as 
potential confounders. Confounding was considered present if the estimated, unadjusted odds 
ratio changed by more than 15%. The confounding analysis identified lifetime history of drug 
treatment as a positive confounder of the association between HCV disclosure and both gender 
and education. Consequently, lifetime history of drug treatment was required to be in the final 
model. Covariates in the initial multivariate model included gender, age, race, education, marital 
status, unemployment, dependence on someone else for majority of support, lifetime history of 
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IDU, spend most of free time alone, social conflict, lifetime history of drug treatment, and time 
since HCV diagnosis. The final model was derived through manual backward elimination with 
critical=0.05, and included age, lifetime history of drug treatment, and time since HCV diagnosis. 
 
Respondent-driven sampling weights were not applied to the data because rather than calculating 
population estimates of HCV disclosure, this study focused on correlates of HCV disclosure in 
this sample of rural, high-risk drug users. Collinearity within the model was assessed in both the 
full and final models using the %COLLIN_2011 macro.36 Covariates did not exceed a condition 
index of 30 in either the full or final model, indicating that multicollinearity was not present in 
either multivariate model.  
 
Results 
 
Participant Characteristics 
Participants (n=243) were primarily male (57.2%), white (93.0%), and had at least a high school 
education (54.3%). The mean age was 33.8 years (range 20.5-56.5). While all participants were 
HCV antibody positive, only 32.9% sough confirmatory testing, and only 4.9% sought treatment 
for HCV. Among those who sought confirmatory testing (n=80), the majority (85.0%) reported 
testing positive on the second test and being told they have HCV. Most (77.0%) tested HCV-
positive for the first time within the SNAP study. The median duration since HCV diagnosis was 
8.8 years (IQR 5.9) and 4.2 years (IQR 1.4) for participants who tested positive prior to entering 
the study and during the study, respectively; the overall mean duration since HCV diagnosis was 
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5.0 years (range 0.4-22.3). Demographic, behavioral, and interpersonal characteristics are 
presented in Table 1. 
 
HCV-positive Status Disclosure and Correlates 
Most participants (69.1%) reported disclosing their HCV-positive status to at least one of their 
social referents (Table 2). Individuals who disclosed their HCV-positive serostatus most 
commonly disclosed to current sex partners (63.7%), family members (51.8%), close friend(s) 
(13.7%), or past sex partners (9.5%). Few participants disclosed to current IDU partners (3.8%, 
calculated among 72 who reported injecting within the past six months), spouses (if married) 
(2.9%), or past IDU partners (1.4%, calculated among 215 who reported ever injecting drugs). 
 
Results from unadjusted logistic regression analyses are presented in Table 1. Estimated, 
unadjusted odds ratios, 95% confidence intervals, and p-values are provided to show associations 
between covariates and HCV-positive status disclosure. None of the demographic, behavioral, or 
interpersonal characteristics assessed were significantly associated with HCV disclosure. 
Lifetime history of drug treatment was significantly associated with non-disclosure of HCV-
positive status. Participants with a lifetime history of drug treatment had 60% lesser odds of 
disclosing their HCV-positive status than those participants who had no history of drug treatment 
(odds ratio [OR]: 0.40; 95% CI [0.23, 0.70]). Of note, there was no evidence of a dose-response 
relationship between weeks spent in drug treatment in the prior year and HCV disclosure (data 
not shown in table).    
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Table 3 presents the results from the final multivariate logistic regression model (n=243). 
Adjusting for all other covariates in the model, age (p=0.043) and lifetime history of drug 
treatment (p=0.001) were independently associated with HCV-positive status disclosure. Time 
since HCV diagnosis (p=0.782) was maintained in the final model to control for the effects of 
varying duration of serostatus awareness. Holding all other covariates constant, a one year 
increase in age corresponded to a 4% reduction in the odds of disclosing HCV-positive status 
(AOR: 0.96, 95% CI [0.93, 1.00]). A lifetime history of drug treatment corresponded to a 61% 
reduction in the odds of disclosing HCV-positive status compared to participants without a 
history of drug treatment, adjusting for the other covariates in the model (AOR: 0.39, 95% CI 
[0.22, 0.69]). 
 
Discussion 
 
To the author’s knowledge, this is the first study of its kind to quantitatively assess correlates of 
HCV serostatus disclosure among rural drug users. The purpose of this study was to identify 
demographic, behavioral, and interpersonal characteristics associated with HCV disclosure 
among high-risk drug users in Appalachian Kentucky. Notably, 30.9% of participants did not 
disclose their HCV-positive status to anyone. Among individuals who did disclose their 
serostatus, disclosure to those social referents potentially at greatest risk for infection through 
percutaneous transmission was rare (3.8% among current, and 1.4% among past IDU partners, 
respectively). Overall, the results of this study suggest that older age and lifetime history of drug 
treatment are associated with a decrease in the odds of HCV disclosure.  
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An association between age and disclosure has previously been identified in the HIV 
literature,37,38 but not in the HCV literature. A recent study found that older adults (50 years 
old) were less likely to disclose HIV than younger adults (20-39 years old).37 Post-hoc, gender-
stratified analyses in this study revealed that age was associated with HCV disclosure only 
among women (p=0.006). These data suggest that older women are less likely as a group to 
disclose their HCV-positive status than younger women, while age does not significantly 
influence male disclosure patterns. The reasons for this are likely multifactorial, but may be 
related to a greater perception of social stigma surrounding drug use among older women 
compared to younger women or even men. A small, qualitative study of older (50 years of age) 
HIV-positive women in the southeastern United States supports this hypothesis: the women 
reported being reluctant to disclose their status because they viewed it as more shameful at their 
older ages.38 
 
The negative association between lifetime history of drug treatment and HCV disclosure had not 
been identified in previous literature, and was an unexpected and novel finding of this study. 
Although the nearly three-fold decrease in odds of disclosure among those with a lifetime history 
of drug treatment seems counterintuitive, it is possible that individuals whose drug treatment was 
court-ordered (as was the case in 52% with a lifetime history of drug treatment in the study) were 
more reluctant to disclose their HCV-positive status out of fear that it would be seen as an 
admission of prior or current drug use, which could violate their probation. Additionally, 
individuals who successfully completed drug treatment may have a new social identity of being 
abstinent, and might consider HCV disclosure irrelevant in their current milieu. The result 
suggests that interventions aimed at increasing HCV disclosure should partner with drug 
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treatment providers to clarify misperceptions among patients of the potential consequences and 
benefits of disclosing one’s HCV serostatus. 
 
This study is not without limitations. These data are cross-sectional; consequently, inferences 
about causality or temporality are not possible. Second, as a result of the small sample size, the 
analysis may have lacked the statistical power to detect small differences among some of the 
covariates, potentially increasing the probability of type II error. Third, the homogeneity of this 
rural, Appalachian sample may limit generalizability of the results to more diverse urban or rural 
population groups. Similarly, the fact that this study population is in the midst of an acute HCV 
epidemic3,28 may limit its generalizability beyond other settings experiencing increased acute 
HCV incidence. Fourth, behavioral and demographic data were self-reported and subject to recall 
and social desirability bias. Of note, HCV serostatus was not self-reported, and this was a 
strength of the study. Fifth, information about disclosure in particular relationships (such as 
duration of relationship or frequency of interaction) was not available. However, it does not 
appear that the tendency to disclose to sex partners is related to frequency of contact, and on 
average participants reported injecting more frequently in the prior 30 days than having sex. 
Finally, serostatus in this study was based on HCV antibody testing rather than RNA testing; 
antibody testing does not necessarily correlate with active HCV infection. However, a prior 
random sample of HCV antibody-positive participants from the study cohort revealed that 69% 
were HCV RNA-positive,39 suggesting a high potential for transmission and reinforcing the 
importance of HCV disclosure, particularly to injection risk partners. 
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Despite these limitations, this study provides important insight into demographic, behavioral, and 
interpersonal correlates of HCV serostatus disclosure among high-risk drug users in rural 
Appalachia. Most striking was the almost complete absence of disclosure to current or former 
IDU partners, the social referents theoretically at highest risk of HCV infection given the 
efficiency of percutaneous transmission. Current post-test counseling guidelines for HCV testing 
do not mention disclosure.40 Incorporating educational messages related to the importance of 
HCV disclosure into post-test counseling might help curtail the further spread of HCV. Findings 
from this study suggest that messages targeted at older women should be prioritized since this 
group was identified as being especially hesitant to disclose HCV status. Partnering with drug 
treatment providers on interventions may represent another method to encourage HCV disclosure 
as a normative behavior among those most at risk of transmitting, or becoming infected with, 
HCV.  
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Table 1. Demographic and behavioral characteristics of sample and univariate associations with 
HCV disclosure (n=243) 
 
Characteristic Total n (%) Disclosed 
HCV-positive 
status, n (%) 
Crude 
OR 
95% CI p-value 
Demographic      
Male 139 (57.2) 92 (54.8) 0.72 (0.41, 1.26) 0.251 
Age (years), mean (SD) 33.8 (7.8) 33.2 (7.5) 0.97 (0.93, 1.00) 0.054 
White 226 (93.0) 158 (94.1) 1.63 (0.59, 4.45) 0.344 
High school graduate 132 (54.3) 90 (53.6) 0.91 (0.52, 1.57) 0.726 
Currently married 46 (18.9) 35 (20.8) 1.53 (0.73, 3.21) 0.260 
Unemployed 106 (43.6) 78 (46.4) 1.46 (0.83, 2.54) 0.188 
Interpersonal      
Spends most of free time 
alone 
71 (29.2) 49 (29.2) 0.99 (0.55, 1.80) 0.979 
Social conflict 31 (12.8) 20 (11.9) 0.79  (0.36, 1.74) 0.552 
Dependent on someone else 
for majority of support 
83 (34.2) 58 (34.5) 1.05 (0.59, 1.88) 0.857 
Other characteristics      
Lifetime history of IDU 215 (88.5) 144 (85.7) 0.34 (0.11, 1.01) 0.052 
Lifetime history of drug 
treatmenta 
105 (43.2) 61 (36.3) 0.40 (0.23, 0.70)  0.001** 
Time since HCV diagnosis 
(years), mean (SD)  
5.0 (3.5) 5.0 (3.7) 0.99 (0.92, 1.07) 0.764 
HCV=Hepatitis C virus; OR=Odds ratio; CI=Confidence interval; SD=Standard deviation 
a Drug treatment includes methadone detoxification, methadone maintenance, Outpatient Drug 
Free, residential treatment, non-methadone detoxification, and 12-step programs (Alcoholics 
Anonymous/ Narcotics Anonymous) 
** p<0.01 
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Table 2. Person-types to whom participants disclosed HCV-positive status (n=243) 
 
Category Disclosed HCV-positive status, n (%) 
Current sex partner  107 (63.7) 
Family member(s)  87 (51.8) 
Close friend(s)  23 (13.7) 
Past sex partner  16 (9.5) 
Current injection drug use partners (n=72)a 2 (3.8) 
Spouse (if married) (n=46)b 1 (2.9) 
Past injection drug use partners (n=215)c 2 (1.4) 
a Calculated among the 72 participants who reported injection drug use in the past 6 months 
b Calculated among the 46 participants who were married 
c Calculated among the 215 participants who reported ever injecting drugs 
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Table 3. Multivariate analysis of correlates to HCV disclosure (n=243) 
 
Characteristic Adjusted OR 95% CI p-value 
Age 0.96 (0.93, 1.00) 0.043* 
Lifetime history of drug treatment 0.39 (0.22, 0.69)  0.001** 
Time since HCV diagnosis 1.01 (0.93, 1.10) 0.782 
OR=Odds ratio; CI=Confidence interval 
*  p<0.05 
** p<0.01 
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